Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTION, ORAL, RECTALStandard

OMNIPAQUE 180

IOHEXOL

Standard Dose
38.8%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OMNIPAQUE 180 is listed in Drugs@FDA under application 018956 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient IOHEXOL Form and strength SOLUTION;INJECTION, ORAL, RECTAL - 38.8% Sponsor GE HEALTHCARE Submission history Latest submission status date: 2024-10-08 00:00:00.

Structured Monograph

Clinical summary

Approval overview OMNIPAQUE 180 is listed in Drugs@FDA under application 018956 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient IOHEXOL Form and strength SOLUTION;INJECTION, ORAL, RECTAL - 38.8% Sponsor GE HEALTHCARE Submission history Latest submission status date: 2024-10-08 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.